ESR1 and breast carcinoma: Furthermore, PP2A is widely involved in regulating most current developments in targeted therapeutic strategies for TNBCs [27,28], and more importantly, PP2A could induce ER re-expression in ER-negative breast cancer cells, and which would reverse endocrine therapeutic resistance in ER(−) breast cancer, then providing a potential therapeutic strategies for TNBC.